
- Telehealth Visits
- Insurance plan information

Pamela N. Munster, MD
Medical Oncology • HematologyCo-director, Center for BRCA Research- Telehealth Visits
- Insurance plan information
Hereditary Cancer Mission Bay



Pamela N. Munster, MD
Medical Oncology • HematologyCo-director, Center for BRCA ResearchHereditary Cancer Mission Bay
- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Pamela N. Munster is a medical oncologist who cares for patients with breast cancer. Her roles include director of the early-phase clinical trials program for cancer research; co-director of the UCSF Center for BRCA Research; and co-leader of UCSF's program in developmental therapeutics, which focuses on innovative research to find treatments for advanced cancer.
In her own research endeavors, Munster is interested in developing new targeted therapies for treatment-resistant cancer. She studies changes in gene expression and resistance to therapy. Her lab is involved in projects evaluating hormone therapies for breast cancer as well as therapies that engage the immune system to fight tumors. She has published in numerous scientific journals and lectured on topics in breast oncology, such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research (the process of applying study findings to patient care). She has a published memoir, “Twisting Fate: My Journey with BRCA – From Breast Cancer Doctor to Patient and Back.”
Munster earned her medical degree from the University of Bern in Switzerland. She completed a residency in internal medicine at Indiana University Health, followed by a fellowship in medical hematology and oncology at Memorial Sloan Kettering Cancer Center, where she also served as faculty in the breast cancer program.
Prior to joining UCSF, Munster worked for six years in the Moffitt Cancer Center's division of breast oncology and experimental therapeutics program, serving as scientific director of breast research and co-chair of the phase 1 clinical trial program.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
Fellowship
- Hematology - Oncology, Memorial Sloan Kettering Cancer Center (GME)
My expertise
Specialties
Conditions
Locations
My research
Clinical trials
Pilot Study of Pancreatic Cancer ScreeningOpens in a new window
Recruiting
Proportion of participants with an abnormal MRI finding will be reported as an event. An estimated event rate of 19% in participants with a strong family histo...Combination Therapy in Cancers With Mutations in DNA Repair GenesOpens in a new window
Recruiting
The percentage of participants with treatment-emergent adverse events as classified and graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE...A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsOpens in a new window
Recruiting
Number of participants with AEs and SAEs.
Publications
Showing 1-6 of 20 reviews
Sort by
- March 24, 20265 out of 5 Stars
I deal frequently with my oncologist (Dr Munster) and my NP (Susan CALABRESE) --Both are extraordinarily open, attentive and empathetic.
- February 18, 20265 out of 5 Stars
Love Dr Munster
- January 29, 20265 out of 5 Stars
Dr Munster was excellent
- January 21, 20265 out of 5 Stars
Pam Munster, MD is an extraordinary doctor and human being. I feel very lucky for the opportunity to work together.
- January 6, 20265 out of 5 Stars
Wonderful, highly competent and very caring
- December 19, 20255 out of 5 Stars
I can't say enough good things about Dr. Munster.
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.